Review article · 2026 · Open access

RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants: A Systematic Review and Meta-Analysis

Rabab Batool, Ran Wang, Hala Obeid, Tobias R. Kollmann, Joanne M. Langley, Pascal M. Lavoie, Bahaa Abu-Raya

Archives of Pediatrics and Adolescent Medicine, 180(11), 1213 · Published 8 September 2026 · DOI 10.1001/jamapediatrics.2026.4074

Open full textView at the publisherCite this paper

In brief

“RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants: A Systematic Review and Meta-Analysis” is a 2026 review article by Rabab Batool and 6 co-authors, published in Archives of Pediatrics and Adolescent Medicine. OpenAlex counts 1 citations as of 18 November 2026, which puts it in the top 9% of works published in 2026 by citations. It is open access: the full text is free to read at SSRN Electronic Journal.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
0.96
References
36
Authors
7

Abstract

Importance: The respiratory syncytial virus (RSV) bivalent prefusion F protein vaccine (RSVpreF) administered during pregnancy has demonstrated efficacy in protecting infants against early-life RSV disease in the pivotal clinical trial. Objective: To conduct a systematic review and meta-analysis to synthesize real-world evidence on the effectiveness of RSVpreF in preventing RSV-associated lower respiratory tract infection (LRTI) in infants. Data Sources: PubMed, Scopus, and Europe PMC were searched from January 1, 2020, through January 30, 2026. Study Selection: A total of 1144 studies were initially identified. Eligible were nonrandomized studies reporting the effectiveness of RSVpreF vaccine in pregnancy in the prevention of RSV-associated LRTI in infants. Data Extraction and Synthesis: All studies were screened independently by 2 reviewers. Data were extracted on RSV-associated outcomes among infants born to women who received RSVpreF vaccination during pregnancy and infants born to unvaccinated women. Main Outcomes and Measures: The primary outcome was RSV-associated LRTI hospitalization. Odds ratios (ORs) were pooled using random-effects meta-analysis with the Hartung-Knapp adjustment and Sidik-Jonkman estimator. Vaccine effectiveness against RSV-associated LRTI hospitalization was calculated as (1 - OR) × 100% and assessed in infants from birth to age 3 months and from birth to 6 months, separately. The limited available data precluded meta-analysis of effectiveness against the secondary outcomes of RSV-associated emergency department visits, intensive care unit admissions, and death. Results: A total of 7 studies were included, comprising 7112 infants, of whom 2684 were born to vaccinated mothers. The studies collected data from January 2024 through April 2025 from Argentina, the UK, and the US. Pooled vaccine effectiveness against RSV-associated LRTI hospitalization was 82% (95% CI, 81%-82%; 3 studies, 4397 participants; I2 = 0%) in infants from birth to 3 months and 78% (95% CI, 70%-84%; 6 studies, 3008 participants; I2 = 18.7%) in infants from birth to 6 months, when mothers were vaccinated 14 days or more before delivery. Conclusions and Relevance: The results of this systematic review and meta-analysis suggest that postimplementation data support the effectiveness of RSVpreF in pregnancy for the prevention of RSV-associated LRTI hospitalization during the first 6 months of life. The results support the introduction of RSVpreF into routine antenatal immunization programs.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Batool, R., Wang, R., Obeid, H., Kollmann, T. R., Langley, J. M., Lavoie, P. M., & Abu-Raya, B. (2026). RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants: A Systematic Review and Meta-Analysis. Archives of Pediatrics and Adolescent Medicine, 180(11), 1213. https://doi.org/10.1001/jamapediatrics.2026.4074

MLA 9

Batool, Rabab, et al. “RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants: A Systematic Review and Meta-Analysis.” Archives of Pediatrics and Adolescent Medicine, vol. 180, no. 11, 2026, p. 1213. https://doi.org/10.1001/jamapediatrics.2026.4074.

Chicago

Batool, Rabab, Ran Wang, Hala Obeid, Tobias R. Kollmann, Joanne M. Langley, Pascal M. Lavoie, and Bahaa Abu-Raya. 2026. “RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants: A Systematic Review and Meta-Analysis.” Archives of Pediatrics and Adolescent Medicine 180 (11): 1213. https://doi.org/10.1001/jamapediatrics.2026.4074.

Harvard

Batool, R. et al. (2026) ‘RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants: A Systematic Review and Meta-Analysis’, Archives of Pediatrics and Adolescent Medicine, 180(11), p. 1213. doi:10.1001/jamapediatrics.2026.4074.

IEEE

R. Batool et al., “RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants: A Systematic Review and Meta-Analysis,” Archives of Pediatrics and Adolescent Medicine, vol. 180, no. 11, p. 1213, 2026, doi: 10.1001/jamapediatrics.2026.4074.

BibTeX

@article{batool2026bivalent,
  title     = {{RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants: A Systematic Review and Meta-Analysis}},
  author    = {Batool, Rabab and Wang, Ran and Obeid, Hala and Kollmann, Tobias R. and Langley, Joanne M. and Lavoie, Pascal M. and Abu-Raya, Bahaa},
  journal   = {Archives of Pediatrics and Adolescent Medicine},
  year      = {2026},
  volume    = {180},
  number    = {11},
  pages     = {1213},
  doi       = {10.1001/jamapediatrics.2026.4074},
  url       = {https://doi.org/10.1001/jamapediatrics.2026.4074}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Epidemiology › Respiratory viral infections research

  • respiratory syncytial virus
  • RSVpreF vaccine
  • prefusion F protein vaccine
  • vaccine effectiveness
  • infant hospitalization
  • real-world evidence
  • passive immunity
  • emergency department visits

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Batool, R., Wang, R., Obeid, H., Kollmann, T. R., Langley, J. M., Lavoie, P. M., & Abu-Raya, B. (2026). RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants: A Systematic Review and Meta-Analysis. Archives of Pediatrics and Adolescent Medicine, 180(11), 1213. https://doi.org/10.1001/jamapediatrics.2026.4074

How many times has this paper been cited?

1 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at SSRN Electronic Journal: sign in and open the full text from this page.

Who wrote this paper?

Rabab Batool, Ran Wang, Hala Obeid, Tobias R. Kollmann, Joanne M. Langley, Pascal M. Lavoie, Bahaa Abu-Raya.

What is the DOI of this paper?

10.1001/jamapediatrics.2026.4074, permanently at https://doi.org/10.1001/jamapediatrics.2026.4074. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.